GEFITINIB Drug Patent Profile

Which patents cover Gefitinib, and what generic alternatives are available?

Gefitinib is a drug marketed by Actavis Labs Fl Inc, Apotex, Cipla, Natco, and Qilu Pharm Hainan. and is included in five NDAs.

The generic ingredient in GEFITINIB is gefitinib. Five suppliers are listed for this compound. Additional details are available on the gefitinib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gefitinib

A generic version of GEFITINIB was approved as gefitinib by QILU PHARM HAINAN on February 13^th, 2023.

Summary for GEFITINIB

US Patents:	0
Applicants:	5
NDAs:	5

US Patents and Regulatory Information for GEFITINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	GEFITINIB	gefitinib	TABLET;ORAL	208913-001	Apr 26, 2023	AB	RX	No	No
Natco	GEFITINIB	gefitinib	TABLET;ORAL	212827-001	May 31, 2023	AB	RX	No	No
Apotex	GEFITINIB	gefitinib	TABLET;ORAL	209532-001	Sep 23, 2022		DISCN	No	No

Gefitinib Investment Analysis: Patent Expiration, FDA Status, Market Fundamentals, and Generic Risk

Last updated: August 1, 2026

Gefitinib is a mature, off-patent EGFR tyrosine kinase inhibitor with limited branded investment value and continuing clinical utility in EGFR-mutated non-small-cell lung cancer. AstraZeneca’s Iressa franchise no longer has meaningful U.S. exclusivity. The investment case is primarily based on low-cost generic manufacturing, emerging-market volume, oncology distribution, and potential use in biomarker-driven treatment programs. Patent-based pricing power is substantially exhausted.

What is gefitinib and how does it work?

Gefitinib is an oral small-molecule inhibitor of the epidermal growth factor receptor, or EGFR, tyrosine kinase. It inhibits signaling from activating EGFR mutations, particularly exon 19 deletions and the L858R substitution in exon 21.

The drug is marketed in 250 mg tablets. Its principal indication is the treatment of patients with metastatic non-small-cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test (FDA, 2024a).

Gefitinib is most commercially relevant in:

• EGFR-mutated non-small-cell lung cancer
• First-line targeted therapy in regions where lower-cost EGFR inhibitors are used
• Markets with limited access to newer third-generation agents
• Treatment settings where osimertinib, afatinib, or other newer drugs are unavailable or unaffordable

Gefitinib is not a biologic. Biosimilar competition is therefore irrelevant. Its competitive risks come from generic small-molecule products, newer EGFR inhibitors, local manufacturers, and clinical preference for agents with stronger resistance and central-nervous-system activity.

What is the FDA status of gefitinib?

Gefitinib received accelerated FDA approval in 2003 for previously treated, locally advanced or metastatic non-small-cell lung cancer. The product was withdrawn from the U.S. market in 2012 after confirmatory-trial requirements were not completed in a manner that supported broad use.

The FDA approved gefitinib again in July 2015 for metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions. The reapproval was biomarker-specific and based on improved patient selection rather than a return to unrestricted NSCLC use (FDA, 2015).

Key FDA milestones

Event	Date	Commercial significance
Original FDA approval	May 2003	Established Iressa as an EGFR-targeted NSCLC product
U.S. marketing withdrawal	2012	Reduced U.S. commercial continuity
Biomarker-specific reapproval	July 2015	Restored a defined U.S. indication
Generic FDA approvals	2017 onward	Removed most remaining U.S. product differentiation
Current use	Ongoing	Restricted to EGFR mutation-positive metastatic NSCLC

The current U.S. label requires molecular identification of an activating EGFR mutation. This limits empirical use and makes companion-diagnostic access a commercial requirement.

When does gefitinib lose exclusivity?

Gefitinib has already lost meaningful U.S. market exclusivity. The original branded product was protected by a combination of compound, formulation, regulatory, and method-of-use rights, but the relevant U.S. exclusivity period has ended.

The key commercial dates are:

Exclusivity category	Approximate status
U.S. compound-patent protection	Expired
U.S. formulation and product patents	Expired or commercially ineffective
FDA orphan-drug exclusivity	Not the principal protection for gefitinib
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired
Current U.S. position	Generic competition

The exact expiration date of an individual patent depended on patent-term adjustment, terminal disclaimers, and the specific claim set. For investment purposes, the controlling fact is that multiple generic manufacturers have entered the U.S. market, demonstrating that the core Orange Book barriers no longer prevent competition.

What patents protect gefitinib?

The original patent estate covered quinazoline compounds, including gefitinib, pharmaceutical compositions, and therapeutic use. AstraZeneca and related entities held the principal branded rights.

Principal patent categories

Patent category	Protected subject matter	Current value
Compound patents	Quinazoline EGFR inhibitors, including gefitinib	Expired
Composition patents	Gefitinib tablets and pharmaceutical formulations	Expired or weak
Method-of-use patents	Treatment of EGFR-associated cancers	Mostly expired
Diagnostic rights	EGFR mutation testing and patient selection	Usually held by separate diagnostic parties
Manufacturing patents	Synthetic intermediates and processes	Limited if nonessential or expired

The original compound patent family was the most commercially important asset. Once it expired, later formulation and method patents could not preserve branded pricing unless they covered a clinically necessary and non-substitutable product characteristic. Gefitinib’s conventional immediate-release tablet does not create a durable formulation moat.

How strong is the gefitinib patent estate?

The current patent estate is weak from an investment perspective.

Patent strength is limited by:

1. Expiration of core composition-of-matter rights.
2. Availability of alternative synthetic routes.
3. Lack of a protected differentiated delivery system.
4. Generic substitution at the active-ingredient level.
5. Clinical competition from newer EGFR inhibitors.
6. Low switching costs for payers and hospitals.

Manufacturing patents may still matter in individual jurisdictions if they cover a commercially efficient route and remain enforceable. Their value is generally tactical rather than franchise-defining.

What is the Orange Book status of gefitinib?

Gefitinib is listed in the FDA Orange Book through the branded Iressa reference product and generic equivalents. The Orange Book identifies approved products, dosage forms, strengths, and patent or exclusivity information relevant to abbreviated new drug applications.

Generic applicants could challenge listed patents through Paragraph IV certifications once the relevant patent barriers became vulnerable. Because the major protection has expired, the present competitive environment is dominated by approved generic products rather than active brand litigation.

U.S. dosage form

• Active ingredient: gefitinib
• Strength: 250 mg
• Route: oral
• Dosage form: tablet
• Reference product: Iressa
• Therapeutic class: EGFR tyrosine kinase inhibitor
• Generic pathway: Abbreviated New Drug Application

The commercial importance of Orange Book listings is now limited to confirming substitutability and identifying any residual listed claims. They do not provide AstraZeneca with a practical basis for maintaining premium U.S. pricing.

Which companies are challenging gefitinib?

The principal challenge comes from generic manufacturers rather than a single high-profile Paragraph IV litigant.

U.S. generic supply has included manufacturers such as:

• Teva Pharmaceuticals
• Mylan, now part of Viatris
• Cipla and other international manufacturers in non-U.S. markets
• Regional oncology suppliers operating under country-specific approvals

The competitive set varies by jurisdiction. In India, China, and other Asian markets, local manufacturers have supplied gefitinib for years. These companies compete on price, hospital tenders, distribution reach, and regulatory access.

A generic company’s ability to enter does not depend solely on patent status. It also depends on:

• Bioequivalence approval
• Manufacturing-site compliance
• Active pharmaceutical ingredient supply
• Local registration
• Pharmacovigilance capability
• Hospital procurement access
• Ability to support mutation-testing programs

What patent litigation affects gefitinib?

Gefitinib’s major U.S. litigation cycle was associated with the original Iressa product and generic entry. The commercial significance of that litigation has largely passed because core rights have expired and multiple generic products are available.

Current litigation risk is more likely to involve:

• Patent challenges to manufacturing processes
• Local-country product registrations
• Trademark disputes involving Iressa or similar names
• Regulatory exclusivity disputes
• Patent enforcement over combination regimens
• Diagnostic or biomarker-testing claims

A generic manufacturer could still face jurisdiction-specific litigation if it relies on a patented process or markets an unapproved indication. Those risks are separate from the expired core gefitinib composition patent.

What generic entry risks exist for gefitinib?

Generic entry risk is high and largely realized.

Risk factor	Assessment	Effect
Core patent expiry	High	Removes composition-of-matter barrier
Number of potential manufacturers	High	Creates price competition
Product complexity	Low to moderate	Conventional tablet is relatively simple
API availability	Moderate	Supply concentration can affect margins
Switching costs	Low	Payers can substitute products
Brand loyalty	Low in mature markets	Prescribing is driven by price and mutation status
Clinical differentiation	Weak versus newer agents	Limits premium pricing
Regulatory barriers	Moderate	Manufacturing compliance remains important

Generic gefitinib does not require the development infrastructure associated with injectable biologics or complex drug-device combinations. That supports entry, although oncology products still require reliable quality control and supply continuity.

How does gefitinib compare with other EGFR inhibitors?

Gefitinib is generally disadvantaged clinically against newer EGFR inhibitors, particularly in markets where third-generation therapy is accessible.

Drug	Generation	Key commercial position	Main competitive advantage
Gefitinib	First	Low-cost generic EGFR therapy	Price and established use
Erlotinib	First	Generic EGFR therapy	Broad historical use
Afatinib	Second	Generic or lower-cost targeted therapy	Irreversible EGFR-family inhibition
Osimertinib	Third	Premium targeted therapy	Activity against T790M and stronger CNS positioning
Dacomitinib	Second	Limited commercial role	Irreversible pan-ErbB inhibition

Osimertinib has the strongest clinical and commercial position in many developed markets because of its efficacy in the first-line setting and activity against central nervous system disease. Gefitinib remains relevant when price, formulary access, or local guidelines favor older EGFR inhibitors.

The principal risk is not rapid total displacement. It is gradual migration of higher-value patients to newer therapies, leaving gefitinib concentrated in price-sensitive markets.

What formulations are protected by gefitinib patents?

The commercial product is a conventional immediate-release oral tablet. There is no widely adopted long-acting injectable, extended-release, inhaled, or implantable gefitinib formulation with a material market position.

This limits lifecycle-management options. A formulation patent could be valuable only if it produced one or more of the following:

• Better absorption
• Reduced food effect
• Lower toxicity
• Improved adherence
• More convenient dosing
• Combination delivery
• Better central nervous system exposure

No such differentiated formulation has displaced the standard 250 mg tablet in the major gefitinib markets. Generic manufacturers can therefore compete directly with the reference product.

What is the commercial outlook for gefitinib?

Gefitinib is a volume-and-access product rather than a high-margin innovation asset.

Revenue exposure

AstraZeneca’s historical Iressa revenue has declined sharply from its earlier commercial period as a result of generic entry, competitive displacement, and geographic market differences. Current revenue exposure is not comparable with the company’s major oncology franchises, including Tagrisso, Imfinzi, and Enhertu.

For generic manufacturers, the opportunity is different. Gefitinib can generate attractive returns when a company has:

• Low-cost API sourcing
• A compliant tablet facility
• Established oncology distribution
• Access to public tenders
• Registration in high-prevalence EGFR-mutated populations
• A broad portfolio of generic cancer medicines

The product is unlikely to support premium pricing in the United States. Emerging markets may offer better volume, but price controls, tender pressure, currency risk, and local competition reduce profitability.

Market fundamentals

The underlying demand drivers are durable:

• Lung cancer remains one of the largest global cancer markets.
• EGFR mutations are common in Asian populations and occur in a meaningful minority of Western patients.
• Molecular testing expands the addressable population for targeted therapy.
• Oral administration reduces administration costs.
• Generic pricing improves access where premium EGFR inhibitors are unaffordable.

The negative drivers are equally clear:

• Osimertinib is preferred in many treatment guidelines.
• Generic competition is intense.
• Treatment duration can be affected by acquired resistance.
• Gefitinib has limited value in EGFR wild-type tumors.
• Reimbursement is increasingly linked to molecular testing and guideline placement.

What licensing deals affect gefitinib?

AstraZeneca developed and commercialized Iressa globally. The current investment opportunity is not based on a major active global licensing transaction. Local licensing, supply, and distribution agreements may exist in individual countries, but these arrangements generally support market access rather than create defensible intellectual property.

Potential transaction value lies in:

• Regional generic commercialization rights
• Contract manufacturing
• API supply agreements
• Oncology portfolio bundling
• Distribution partnerships in countries with high EGFR-mutated NSCLC prevalence
• Companion-diagnostic partnerships

A licensing deal involving gefitinib alone would generally have limited strategic value unless it provides access to a large regulated market or is bundled with a broader oncology portfolio.

What generic launch scenarios exist for gefitinib?

Scenario 1: Price-led mature-market erosion

In the United States and other regulated markets, several generic suppliers compete on price. Revenue declines, but supply remains stable. This is the base case.

Scenario 2: Emerging-market volume growth

A manufacturer expands in India, China, Southeast Asia, Latin America, or the Middle East. Volume increases, but tender pricing limits margin expansion.

Scenario 3: Clinical displacement

Physicians increasingly choose osimertinib or another newer EGFR inhibitor. Gefitinib becomes concentrated in lower-income markets and second-tier formularies.

Scenario 4: Supply disruption

API or manufacturing failures temporarily increase prices or create shortages. This may benefit alternate suppliers, but the effect is episodic and does not create durable patent value.

Scenario 5: Combination or repurposing strategy

A company develops a protected combination or new indication involving gefitinib. This could create incremental value, but it would require clinical evidence, regulatory approval, and a patent claim that avoids easy substitution with another EGFR inhibitor.

How does geographic coverage affect gefitinib investment value?

Gefitinib’s strongest volume opportunity is in countries with high EGFR mutation prevalence and broad generic use.

Region	Commercial profile
United States	Generic, price-sensitive, biomarker-restricted
Europe	Generic competition and guideline-driven use
China	Large EGFR-mutated NSCLC population; strong domestic competition
India	High generic penetration and price competition
Southeast Asia	Potentially attractive volume with variable reimbursement
Latin America	Access-driven demand, regulatory fragmentation
Middle East and Africa	Lower penetration but potential public-sector demand

China is strategically important because of its large lung-cancer population and high rate of EGFR mutations. It is also one of the most competitive markets, with domestic manufacturers and newer targeted therapies competing for the same patients.

What manufacturing and IP barriers remain?

The main remaining barriers are operational rather than patent-based.

Manufacturers must manage:

• API purity and impurity controls
• Consistent tablet dissolution
• Stability under local climatic conditions
• Good Manufacturing Practice inspections
• Bioequivalence requirements
• Pharmacovigilance reporting
• Anti-counterfeit packaging
• Reliable oncology distribution

The active ingredient is chemically established, and the tablet is not technically complex. Process knowledge and quality systems may create temporary advantages, but they do not replicate the economic protection of an unexpired composition patent.

Is gefitinib a good pharmaceutical investment?

Gefitinib is a weak standalone branded investment and a potentially viable generic portfolio product.

Attractive characteristics

• Established efficacy in EGFR-mutated NSCLC
• Large global lung-cancer burden
• Oral tablet with manageable manufacturing complexity
• Strong demand in cost-sensitive markets
• Low development risk for approved generic products
• Potential portfolio synergies with oncology diagnostics and medicines

Limiting characteristics

• Core exclusivity has expired
• U.S. pricing power is minimal
• Generic competition is widespread
• Osimertinib has stronger clinical positioning
• No major formulation moat
• Revenue growth depends on volume, access, and geographic expansion
• Manufacturing and regulatory execution determine returns

The most defensible investment thesis is a low-cost, compliant generic platform with geographic reach. A premium branded strategy is difficult to justify without a new formulation, combination, biomarker application, or differentiated clinical outcome.

Key Takeaways

• Gefitinib is an established EGFR-targeted therapy for mutation-positive metastatic NSCLC.
• AstraZeneca’s Iressa franchise has no meaningful remaining U.S. composition-of-matter exclusivity.
• Generic entry is widespread and is the principal commercial force.
• Biosimilar risk does not apply because gefitinib is a small molecule.
• Osimertinib is the strongest clinical competitor in many developed markets.
• Gefitinib retains value in price-sensitive and emerging markets with high EGFR mutation prevalence.
• The tablet has limited formulation differentiation and weak lifecycle-management protection.
• Generic manufacturers can achieve returns through low-cost production, tenders, and regional distribution.
• The main barriers are manufacturing quality, regulatory compliance, API supply, and market access.
• Gefitinib is better viewed as a mature generic oncology product than as a protected pharmaceutical franchise.

FAQs

Is gefitinib still patented in the United States?

The core U.S. patents covering gefitinib have expired, and approved generic products are available. Residual patent claims, if any, do not prevent broad generic competition.

Can gefitinib be substituted for osimertinib?

Gefitinib and osimertinib are not clinically interchangeable in every setting. Osimertinib is often preferred because of its resistance profile and central nervous system activity. Treatment selection depends on mutation status, guideline position, patient characteristics, reimbursement, and local availability.

Does gefitinib require a companion diagnostic?

The FDA-approved U.S. indication requires confirmation of an EGFR exon 19 deletion or exon 21 L858R substitution using an FDA-approved test. Molecular testing is therefore central to compliant prescribing.

Is gefitinib profitable for generic drug companies?

It can be profitable when produced at low cost and sold through established oncology channels. Profitability is constrained by price competition, tender procurement, local registration costs, and competition from other EGFR inhibitors.

Could a new gefitinib formulation restore exclusivity?

A clinically meaningful new formulation could receive patent protection and regulatory exclusivity in some circumstances. The commercial impact would depend on improved safety, exposure, adherence, or efficacy and on whether physicians and payers considered the formulation superior to generic tablets.

References

1. AstraZeneca. (2015). Iressa (gefitinib) prescribing information. AstraZeneca Pharmaceuticals LP.

2. European Medicines Agency. (2024). Iressa: EPAR product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (2015). FDA approves gefitinib for metastatic non-small cell lung cancer. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024a). Iressa (gefitinib) label. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

6. National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Non-small cell lung cancer. National Comprehensive Cancer Network.

7. World Health Organization. (2024). Global cancer observatory: Lung cancer. International Agency for Research on Cancer.